Vivimed Labs Share News - Latest Updates, Live News & More

Latest news about Vivimed Labs

Vivimed Labs reports widened net loss in FY26 amid CIRP 5 days ago

Vivimed Labs Limited reported a widened consolidated net loss of ₹1,764.72 million for FY26, with revenue from operations falling to ₹699.89 million. Total expenses increased to ₹2,526.43 million. Auditors SVRL & Co. issued a qualified opinion due to unrecorded interest expenses of ₹625.72 million, leading to an understatement of loss. The NCLT admitted a petition and initiated CIRP on April 15, 2026, with the first Committee of Creditors meeting held on May 13, 2026.

Vivimed Labs confirms no encumbrance on promoter shares in FY26 Jun 18, 2026

Vivimed Labs postpones board meeting for FY26 results May 31, 2026

Vivimed Labs Schedules Board Meeting on May 28, 2026 to Approve Q4FY26 Financial Results May 17, 2026

Vivimed Labs Limited Enters Corporate Insolvency Resolution Process Apr 26, 2026

More news about Vivimed Labs

23Apr 26

Vivimed Labs Limited Insolvency Process: CIRP Commences 15.04.2026

NCLT Bengaluru admitted Vivimed Labs Limited to CIRP on 15.04.2026 over unpaid operational debt of ₹2,78,60,844 owed to Blue Cube Germany Assets. T Narayana Swamy appointed as IRP. Creditors must submit claims by 01.05.2026. The tribunal imposed a moratorium under Section 14 of IBC, prohibiting legal proceedings and asset transfers. Multiple insolvency petitions are pending against the company, indicating broader financial difficulties.

08Apr 26

Vivimed Labs Submits Q4FY26 SEBI Compliance Certificate to Stock Exchanges

Vivimed Labs Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4FY26 to BSE and NSE, confirming adherence to dematerialization requirements. The certificate, received from RTA Aarthi Consultants Private Limited, covers the period from January 1, 2026 to March 31, 2026, representing routine regulatory compliance for depository operations.

13Mar 26

Vivimed Labs Reports Widened Q3 FY26 Loss at ₹165.66 Million on Lower Revenue

Vivimed Labs Limited reported significantly worsened financial performance for Q3 FY26 with net loss widening to ₹165.66 million from ₹74.45 million in Q3 FY25, while revenue declined to ₹116.31 million from ₹186.59 million. Nine-month results showed similar deterioration with loss increasing to ₹295.07 million and revenue falling to ₹342.33 million. Consolidated results mirrored standalone trends with Q3 FY26 loss at ₹165.54 million. Auditors expressed qualified conclusions citing unprovided interest charges of ₹164.52 million for the quarter and ongoing forensic audit evaluations.

Vivimed Labs

5.20

-0.06

(-1.14%)

1 Year Returns:-80.45%

Industry Peers

Sun Pharmaceutical

1,976.70

(+0.15%)

Divis Laboratories

7,425.00

(+0.15%)

Torrent Pharmaceuticals

4,898.30

(-2.41%)

Cipla

1,444.60

(+2.50%)

Zydus Life Science

1,099.20

(-0.81%)

Lupin

2,395.80

(-0.59%)

Mankind Pharma

2,617.90

(+2.60%)

Laurus Labs

1,758.90

(+2.66%)

Dr Reddys Laboratories

1,135.60

(-1.32%)

Aurobindo Pharma

1,549.20

(-0.01%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104